About US
Contact us
-
CDMO Lonza strikes deal with Allarity Therapeutics to manufacture cancer drug candidate dovitinibAllarity Therapeutics has worked diligently to develop Novartis’ failed cancer drug dovitinib. Now, as the Danish biotech anticipates the drug’s approval for metastatic renal cell carcinoma, it has l2021/9/27
-
Takeda breached its contract with AbbVie by failing to supply prostate cancer drug Lupron, court rulesTwo weeks after siding with Takeda in the Japanese pharma giant's spat with Lupron partner AbbVie, a Delaware judge has issued a separate ruling in favor of AbbVie. In his newestruling,Vi2021/9/27
-
Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analystBy this point in Biogen’s highly scrutinized rollout of Alzheimer’s drug Aduhelm, market watchers expected that thousands of U.S. patients would be on the treatment.That reportedly hasn’t been the ca2021/9/23
-
Novartis reshuffling doesn't portend a pullback from gene therapy, company saysTwo months ago, Novartis Gene Therapies chief Dave Lennon left the company to lead a biotech startup that is operating in stealth mode. It was with similar stealth that the unit Lennon formerly heade2021/9/23
-
With new facility and leadership, CDMO Genezen is stepping up to the big leaguesAs a young baseball player, moving from Cave Spring High School to Virginia Tech University was a challenge for Ray Kaczmarek. Three decades later, Kaczmarek finds himself in a similar situation. As2021/9/18
-
Gilead's slumping COVID-19 drug takes another hit with study showing no real benefitLast fall, Gilead Sciences was riding high with its sudden blockbuster Veklury, a failed Ebola drug repurposed for hospitalized COVID-19 patients. But less than a year later, doctors have increasingl2021/9/18
-
Pfizer recalls all Chantix lots nationwide over concerns of cancer-causing impurityPfizer's headache with its popular smoking cessation drug Chantix is escalating. After the drugmaker halted global distribution this summer and then recalled more than a dozen lots in the U.S., the c2021/9/15
-
Biogen's Alzheimer's drug Aduhelm slowly gaining steam among prescribing neurologists, study findsA week ago, Biogen CEO Michel Vounatsos sent the company's shares into a nosedive after disclosing its launch ofAlzheimer’s disease med Aduhelm was slower than expected. But according to one new anal2021/9/15
-
On a dealmaking roll, Sanofi lays out $1.9B for Kadmon and its newly launched transplant drugSanofi has yet to wrap up its $3.2 billion acquisition of mRNA specialist Translate Bio, but the French pharma is already reaching out to its wallet. This time, it’s making a play in general medicine2021/9/9
-
Another discount does the trick: Johnson & Johnson wins NICE backing for prostate cancer drug ErleadaA deeper discount was just the ticket for Johnson & Johnson as it hassecuredreimbursement in England for its prostate cancer drug Erleada. Less than four months ago, the National Institute of Hea2021/9/9